By Pam Belluck and Rebecca Robbins from NYT Health https://ift.tt/3veBqOD
via IFTTT Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients. Health New York Times June 9, 2021 at 07:00PM
No comments:
Post a Comment